We are live on
!
Find out more
C WorldWide Group Portfolio holdings
AUM
$4.15B
Turnover
9.8%
1-Year Est. Return
13.14%
This Fund
S&P 500
This Quarter
Est. Return
-6.69%
1 Year Est. Return
+13.14%
3 Year Est. Return
+63.19%
5 Year Est. Return
+70.18%
10 Year Est. Return
+417.82%
AUM
$4.66B
AUM Growth
-$1.07B
(-19%)
Cap. Flow
-$627M
Cap. Flow
% of AUM
-13.47%
Top 10 Holdings %
Top 10 Hldgs %
60.26%
Holding
100
New
3
Increased
16
Reduced
42
Closed
3
Avg Time Held
4.4
years
Top 10 Avg Time Held
5.2
years
Top 20 Avg Time Held
5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Republic Services
RSG
|
+$77.1M |
| 2 |
Boston Scientific
BSX
|
+$14.4M |
| 3 |
Amer Sports
AS
|
+$7.68M |
| 4 |
Insmed
INSM
|
+$3.84M |
| 5 |
Insulet
PODD
|
+$3.77M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$173M |
| 2 |
Amazon
AMZN
|
+$105M |
| 3 |
Parker-Hannifin
PH
|
+$92.9M |
| 4 |
Exact Sciences
EXAS
|
+$63.5M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$38.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 24.78% |
| 2 | Healthcare | 17.99% |
| 3 | Technology | 14.74% |
| 4 | Industrials | 10.91% |
| 5 | Consumer Discretionary | 9.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
26
Insmed
INSM
$21B
| $26.3M | 0.57% |
161,110
+25,000
| +18% | +$3.84M |
2017 Q1
36 quarters
|
|
27
Penumbra
PEN
$12.6B
| $23.6M | 0.51% |
72,000
| – | – |
2024 Q1
8 quarters
|
|
28
Glaukos
GKOS
$9.67B
| $22.3M | 0.48% |
207,212
| – | – |
2016 Q2
39 quarters
|
|
29
Medtronic
MDT
$121B
| $22.1M | 0.47% |
255,000
| – | – |
2023 Q4
9 quarters
|
|
|
30
Insulet
PODD
$9.82B
| $21M | 0.45% |
99,908
+15,000
| +18% | +$3.77M |
2014 Q3
46 quarters
|
|
31
Vertex Pharmaceuticals
VRTX
$127B
| $20.6M | 0.44% |
46,057
| – | – |
2014 Q3
46 quarters
|
|
32
Elevance Health
ELV
$92.9B
| $19M | 0.41% |
65,000
| – | – |
2017 Q3
34 quarters
|
|
33
Service Corp International
SCI
$11.1B
| $18.9M | 0.41% |
229,430
-16,998
| -7% | -$1.37M |
2019 Q4
25 quarters
|
|
34
Meta Platforms (Facebook)
META
$1.8T
| $18.3M | 0.39% |
32,045
-6,299
| -16% | -$4.04M |
2025 Q3
2 quarters
|
|
35
Krystal Biotech
KRYS
$9.37B
| $17.5M | 0.38% |
67,809
-18,000
| -21% | -$4.79M |
2020 Q1
24 quarters
|
|
36
Neurocrine Biosciences
NBIX
$13.8B
| $16.5M | 0.35% |
125,000
| – | – |
2024 Q2
7 quarters
|
|
37
Sea Limited
SE
$57.5B
| $16M | 0.34% |
193,607
-4,041
| -2% | -$433K |
2020 Q1
24 quarters
|
|
38
BioMarin Pharmaceuticals
BMRN
$10.6B
| $15.1M | 0.32% |
267,851
| – | – |
2014 Q3
46 quarters
|
|
39
Synopsys
SNPS
$87B
| $14.8M | 0.32% |
37,365
-54
| -0.1% | -$24.4K |
2020 Q3
22 quarters
|
|
40
Align Technology
ALGN
$10.5B
| $14.3M | 0.31% |
83,428
| – | – |
2019 Q2
27 quarters
|
|
41
Clean Harbors
CLH
$16.8B
| $14.3M | 0.31% |
49,871
+1,602
| +3% | +$437K |
2024 Q2
7 quarters
|
|
42
MSCI
MSCI
$41.2B
| $13M | 0.28% |
24,208
-36
| -0.1% | -$20.3K |
2019 Q2
27 quarters
|
|
43
Hesai Group
HSAI
$1.95B
| $12.8M | 0.28% |
670,173
-26,960
| -4% | -$680K |
2025 Q3
2 quarters
|
|
44
ResMed
RMD
$33.5B
| $12.6M | 0.27% |
55,939
-81
| -0.1% | -$20.2K |
2020 Q3
22 quarters
|
|
45
Privia Health
PRVA
$2.87B
| $12.5M | 0.27% |
610,000
| – | – |
2022 Q2
15 quarters
|
|
46
Ferguson
FERG
$44.8B
| $12.3M | 0.26% |
52,738
-77,024
| -59% | -$18.7M |
2022 Q3
14 quarters
|
|
47
PTC
PTC
$21B
| $12M | 0.26% |
84,002
-120
| -0.1% | -$19K |
2020 Q3
22 quarters
|
|
48
Vaxcyte
PCVX
$10B
| $11.3M | 0.24% |
195,000
| – | – |
2025 Q1
4 quarters
|
|
|
49
Boston Scientific
BSX
$64.2B
| $11.3M | 0.24% |
+180,000
| New | +$14.4M |
2026 Q1
0 quarters
|
|
50
Waters Corp
WAT
$42.8B
| $10.9M | 0.23% |
36,442
-51
| -0.1% | -$17.4K |
2020 Q3
22 quarters
|
|
Similar funds
C WorldWide Group's Q1 2026 Portfolio in Review
As of Q1 2026, C WorldWide Group held 100 positions worth $4.66B, down 19% from $5.73B the previous quarter. Its ten largest holdings account for 60% of the portfolio.
C WorldWide Group withdrew a net $627M in Q1 2026, closing 3 positions and reducing 42 holdings. Its most notable exit was Procter & Gamble, an estimated $173M position sold in full.
By sector, the portfolio is most concentrated in Financials at 25% of assets, down from 26% a quarter earlier, followed by Healthcare and Technology.
Against the trend, C WorldWide Group opened a new position in Boston Scientific worth $11.3M.
- C WorldWide Group's largest Q1 2026 buy was Boston Scientific: 180,000 shares worth $11.3M.
- C WorldWide Group added most to Republic Services in Q1 2026, an estimated $77.1M increase.
- C WorldWide Group's biggest Q1 2026 reduction was Amazon, cutting an estimated $105M.
- C WorldWide Group fully exited Procter & Gamble in Q1 2026, selling an estimated $173M.
- C WorldWide Group's ten largest holdings make up 60% of its $4.66B portfolio in Q1 2026.
- C WorldWide Group opened 3 new positions and closed 3 in Q1 2026.
- C WorldWide Group's portfolio value fell 19% quarter-over-quarter to $4.66B.
Based on C WorldWide Group's 13F filing for Q1 2026, filed 6 May 2026.